



Pronota Strengthens Management Team

Former VP Corporate Development Genzyme joins as CBO

Ghent, Belgium, 16 March 2012. Pronota NV, the developer of first-in-class diagnostics for early detection of life-threatening conditions, has appointed Carol Greve-Philips as Chief Business Officer and Els Hubloux as Chief Financial Officer.

Pronota has an innovative technology for identifying low quantities of protein circulating in the blood, enabling earlier or better diagnosis of life threatening diseases. Pronota has lead programs in pre-eclampsia, ovarian cancer and sepsis. Pronota is committed to making a difference in diagnosis and personalized healthcare through use of its high value, non-invasive and proprietary protein diagnostic products.

Katleen Verleysen, CEO of Pronota, said: "I'm delighted to have Carol and Els join Pronota, where their substantial business development and investment experience will greatly enhance Pronota resources to drive our products through clinical development to commercialization. With the team in place, I look forward to the establishment of new partnerships."

Carol Greve-Philips is an experienced biotechnology professional with over 20 years of business development skills. She joins Pronota from Genzyme Corporation, where she was Vice President of Corporate Development, responsible for building collaborations with industry partners that brought novel products to the Personalized Genetic Health business. In addition, Carol led successful outlicensing transactions for non-core assets. Carol has also held roles in direct sales, sales management and marketing for Amersham Corporation, Chemsyn Science Laboratories, Watson Laboratories and Toxikon Corporation. Carol has a BSc in Zoology and Chemistry from the University of Massachusetts at Amherst.

Commenting on her appointment, Carol said: "I'm excited to be able to use my extensive business experience gained at Genzyme to support Pronota's development of proprietary innovative diagnostics focused on improving quality of care for patients."

Els Hubloux is an MBA qualified investment professional, originally trained as a chemical engineer, and joins Pronota from Capricorn Venture Partners. Her career encompasses over 16 years of experience in clinical research and development, equity research and venture capital investment. Els has been involved in numerous transactions spanning private and public offerings as well as M&As. Els has both a Chemical Engineering Degree and an MBA from the University of Brussels.

Commenting on her appointment, Els said: "Having secured substantial funding in related fields, I am delighted to be in a position to help grow Pronota's business, working with our solid investor base, and network of renowned key opinion leaders, to support the development of our life-saving programs in maternal health, ovarian cancer, and sepsis."

-Ends-

Enquiries

Pronota

Dr Katleen Verleysen, CEO
+32 (0)92411163
Katleen.verleysen@pronota.com

College Hill (PR agency)

Nicole Yost/Gemma Howe/Daniel Gooch

+44 (0)20 7866 7866

pronota@collegehill.com

About Pronota www.pronota.com

Pronota is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including pre-eclampsia, ovarian cancer and sepsis. Our non-invasive, validated diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare.

About pre-eclampsia

Pre-eclampsia is a medical condition where hypertension arises in pregnancy, in association with protein leakage into the urine. It is the leading causes of maternal deaths in the US and Europe. With over 4 million pregnancies a year in the US alone, there is a compelling health economic argument for the needs for an effective, early pre-eclampsia prediction test. Pronota has a validated test for risk-stratification of pre-eclampsia at 20 weeks of gestation, using the company's proprietary mass-spectrometry based platform for detection and validation of low abundance protein biomarkers.